Loading institutional data...
Loading institutional data...
Held by 531 of 5,944 reporting institutions (97th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| BMRN | $11.5B | 33.3× | 22.1× | 3.6× | 12.9% | 77.7% | 10.8% | 5.7% | 5.2% | 1.2× | 531 |
Peers = companies sharing BMRN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 5%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~1.8% on $597M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $59.91 today, the market must believe free cash flow compounds 11.0%/yr for a decade (off $425M normalized FCF).
The market's 11.0% is more conservative than its 4-yr track record.
2-stage DCF · 0.19B shares · net debt -$715M
mean 167.0% · volatility σ 345% · implied rate exceeded in 3/4 yrs
Central path = implied 11.0%/yr growth; shaded band = ±1σ (345%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $725M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B 100.0% | $2.85B 100.0% | $2.42B 100.0% | $2.10B 100.0% | $1.85B 100.0% | $1.86B 100.0% | $1.70B 100.0% | $1.49B 100.0% | $1.31B 100.0% | $1.12B 100.0% |
| Cost of Revenue | $717.4M 22.3% | $580.2M 20.3% | $532.1M 22.0% | $503.0M 24.0% | $470.5M 25.5% | $524.3M 28.2% | $359.5M 21.1% | $315.3M 21.1% | $241.8M 18.4% | $209.6M 18.8% |
| Research & Development | $921.9M 28.6% | $747.2M 26.2% | $746.8M 30.9% | $649.6M 31.0% | $628.8M 34.1% | $628.1M 33.8% | $715.0M 42.0% | $696.3M 46.7% | $610.8M 46.5% | $661.9M 59.3% |
| Selling, General & Admin | $1.15B 35.8% | $1.01B 35.4% | $892.4M 36.9% | $823.2M 39.3% | $759.4M 41.1% | $737.7M 39.6% | $680.9M 40.0% | $604.4M 40.5% | $554.3M 42.2% | $476.6M 42.7% |
| Total Operating Expenses | $2.81B 87.3% | $2.37B 83.0% | $2.23B 92.3% | $1.94B 92.3% | $1.93B 104.5% | $1.90B 102.3% | $1.80B 105.9% | $1.61B 108.3% | $1.33B 101.1% | $1.92B 171.9% |
| Operating Income | $409.5M 12.7% | $484.2M 17.0% | $185.8M 7.7% | $161.0M 7.7% | -$82.3M -4.5% | -$43.4M -2.3% | -$100.5M -5.9% | -$123.5M -8.3% | -$14.7M -1.1% | -$803.4M -71.9% |
| Interest Expense | $10.9M 0.3% | $12.7M 0.4% | $17.3M 0.7% | $16.0M 0.8% | $15.3M 0.8% | $29.3M 1.6% | $23.5M 1.4% | $43.7M 2.9% | $42.7M 3.3% | $39.5M 3.5% |
| Interest & Investment Income | $74.9M 2.3% | $74.9M 2.6% | $58.3M 2.4% | $18.0M 0.9% | $10.5M 0.6% | $16.6M 0.9% | $22.7M 1.3% | $22.8M 1.5% | $14.9M 1.1% | $7.5M 0.7% |
| Pretax Income | $482.5M 15.0% | $541.8M 19.0% | $188.6M 7.8% | $149.6M 7.1% | -$75.3M -4.1% | -$49.0M -2.6% | -$94.8M -5.6% | -$142.7M -9.6% | -$35.9M -2.7% | -$831.0M -74.4% |
| Income Tax Expense | $133.6M 4.1% | $114.9M 4.0% | $20.9M 0.9% | $8.0M 0.4% | -$11.3M -0.6% | -$903.0M -48.5% | -$71.0M -4.2% | -$65.5M -4.4% | $81.2M 6.2% | -$200.8M -18.0% |
| Net Income | $348.9M 10.8% | $426.9M 15.0% | $167.6M 6.9% | $141.6M 6.8% | -$64.1M -3.5% | $854.0M 45.9% | -$23.8M -1.4% | -$77.2M -5.2% | -$117.0M -8.9% | -$630.2M -56.4% |
| Per Share | ||||||||||
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 |
| Weighted Avg Shares (Basic) | 191.8M | 190.0M | 187.8M | 185.3M | 182.9M | 180.8M | 179.0M | 177.1M | 174.4M | 166.0M |
| Weighted Avg Shares (Diluted) | 197.4M | 196.7M | 191.6M | 189.0M | 182.9M | 191.7M | 179.0M | 177.3M | 174.4M | 166.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-08-05
No material risks flagged.
Where each multiple sits in its own 14-yr range · 25th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 21.1 | 21.1 | 28.2 | 25.5 | 24.0 | 22.0 | 20.3 | 22.3 |
| R&D | 46.7 | 42.0 | 33.8 | 34.1 | 31.0 | 30.9 | 26.2 | 28.6 |
| SG&A | 40.5 | 40.0 | 39.6 | 41.1 | 39.3 | 36.9 | 35.4 | 35.8 |
| Operating Income | -8.3 | -5.9 | -2.3 | -4.5 | 7.7 | 7.7 | 17.0 | 12.7 |
| Income Tax | -4.4 | -4.2 | -48.5 | -0.6 | 0.4 | 0.9 | 4.0 | 4.1 |
| Net Income | -5.2 | -1.4 | 45.9 | -3.5 | 6.8 | 6.9 | 15.0 | 10.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on BMRN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.